First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma

Autor:	Joan Seoane, Michael Lahn, Irene Brana, J. Baselga, Elisabet Sicart, Emiliano Calvo, Ann Cleverly, Ivelina Gueorguieva, Michael A. Carducci, Matthias Holdhoff, J. Rodon Ahnert, Sada Pillay, Jaishri O. Blakeley
Rok vydání:	2011
Předmět:	Cancer Research Kinase business.industry Treatment refractory medicine.disease Transforming growth factor beta receptor I Oncology Glioma Pancreatic cancer Cancer research Medicine In patient business Transforming growth factor
Zdroj:	Journal of Clinical Oncology. 29:3011-3011
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.3011
Popis:	3011 Background: Activated TGF-b signaling has been associated with poor survival in several tumors, including glioma, hepatocellular and pancreatic cancer. TGF-b inhibitors are expected to improve...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::86e7e8edf7806e9c9917b1433f2a142c https://doi.org/10.1200/jco.2011.29.15_suppl.3011 Zobrazit plný text záznamu